TREM2 and glioblastoma: Clinical data indicated that high TREM2 expression in myeloid cells correlates with improved GBM survival, and TREM2 overexpression not only delays GBM progression but also synergizes with anti‐PD‐1 therapy, underscoring the importance of organ‐specific myeloid remodeling [90].